GlassScriptPhysician profile
Sari Kay
NPI 1992009674
$1,799.66
in general payments reported to CMS, 2019-2025
22 companies · $374 in 2025
The $374 reported for 2025 was more than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $36.62 · 2021: $403 · 2022: $325 · 2023: $322 · 2024: $63.54 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $759.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $759.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $522.99 | 2019-2023 | |
| Genzyme Corporation | $474.14 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $167.57 | 2022 | |
| Janssen Biotech, INC. | $141.54 | 2021-2023 | Remicade, Simponi, Stelara |
| Cumberland Pharmaceuticals, INC. | $72.66 | 2021-2023 | Kristalose |
| Mirum Pharmaceuticals, INC. | $44.75 | 2023-2025 | Livmarli, Cholbam, Chenodal |
| Celgene Corporation | $35.60 | 2021 | |
| Merck Sharp & Dohme LLC | $33.65 | 2021 | |
| Albireo Pharma, INC. | $29.78 | 2022 | |
| Qol Medical, LLC | $28.98 | 2022 | |
| Ucb, INC. | $28.87 | 2024 | Nayzilam |
| Sanofi-Aventis U.S. LLC | $27.43 | 2025 | |
| Ascendis Pharma Endocrinology INC | $25.97 | 2023 | |
| Amgen INC. | $25.36 | 2021 | |
| Redhill Biopharma INC. | $24.64 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $23.57 | 2023 | Crysvita |
| Ferring Pharmaceuticals INC. | $22.55 | 2021 | |
| Abbott Laboratories | $19.05 | 2025 | Freestyle Libre 3 |
| Azurity Pharmaceuticals, INC. | $18.57 | 2025 | Triptodur |
| Capsovision, INC. | $18.11 | 2025 | Capsocam Plus |
| Novo Nordisk INC | $13.10 | 2023 | Wegovy |
| Travere Therapeutics, INC. | $0.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sari Kay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.